|
1
|
Asworth T: A case of cancer in which cells
similar to those in the tumours were seen in the blood after death.
Australas Med J. 14:146–147. 1869.
|
|
2
|
Paget S: The distribution of secondary
growths in cancer of the breast. 1889. Cancer Metastasis Rev.
8:98–101. 1989.PubMed/NCBI
|
|
3
|
Fidler IJ: The pathogenesis of cancer
metastasis: The 'seed and soil' hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tibbe AG, Miller MC and Terstappen LW:
Statistical considerations for enumeration of circulating tumor
cells. Cytometry A. 71:154–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park Y, Kitahara T, Urita T, Yoshida Y and
Kato R: Expected clinical applications of circulating tumor cells
in breast cancer. World J Clin Oncol. 2:303–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balic M, Lin H, Williams A, Datar RH and
Cote RJ: Progress in circulating tumor cell capture and analysis:
Implications for cancer management. Expert Rev Mol Diagn.
12:303–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davis JW, Nakanishi H, Kumar VS,
Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T and
Babaian RJ: Circulating tumor cells in peripheral blood samples
from patients with increased serum prostate specific antigen:
Initial results in early prostate cancer. J Urol. 179:2187–2191;
discussion 2191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Braun S, Vogl FD, Naume B, Janni W,
Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G,
et al: A pooled analysis of bone marrow micrometastasis in breast
cancer. N Engl J Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reinholz MM, Nibbe A, Jonart LM, Kitzmann
K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC and Lingle
WL: Evaluation of a panel of tumor markers for molecular detection
of circulating cancer cells in women with suspected breast cancer.
Clin Cancer Res. 11:3722–3732. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zieglschmid V, Hollmann C and Böcher O:
Detection of disseminated tumor cells in peripheral blood. Crit Rev
Clin Lab Sci. 42:155–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parsons HM, Tuttle TM, Kuntz KM, Begun JW,
McGovern PM and Virnig BA: Association between lymph node
evaluation for colon cancer and node positivity over the past 20
years. JAMA. 306:1089–1097. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hermanek P, Hutter RV, Sobin LH and
Wittekind C: International Union Against Cancer. Classification of
isolated tumor cells and micrometastasis. Cancer. 86:2668–2673.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singletary SE, Patel-Parekh L and Bland
KI: Treatment trends in early-stage invasive lobular carcinoma: A
report from the National Cancer Data Base. Ann Surg. 242:281–289.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Broersen LH, van Pelt GW, Tollenaar RA and
Mesker WE: Clinical application of circulating tumor cells in
breast cancer. Cell Oncol (Dordr). 37:9–15. 2014. View Article : Google Scholar
|
|
16
|
Fehm T, Hoffmann O, Aktas B, Becker S,
Solomayer EF, Wallwiener D, Kimmig R and Kasimir-Bauer S: Detection
and characterization of circulating tumor cells in blood of primary
breast cancer patients by RT-PCR and comparison to status of bone
marrow disseminated cells. Breast Cancer Res. 11:R592009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McShane LM, Hunsberger S and Adjei AA:
Effective incorporation of biomarkers into phase II trials. Clin
Cancer Res. 15:1898–1905. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pantel K and Alix-Panabières C:
Circulating tumour cells in cancer patients: Challenges and
perspectives. Trends Mol Med. 16:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
García-Sáenz JA, Martín M, Maestro ML,
Vidaurreta M, Veganzones S, Rafael S, Casado A, Bobokova J, Sastre
J, De la Orden V, et al: Circulating tumour cells in locally
advanced breast cancer. Clin Transl Oncol. 11:544–547. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lianidou ES and Markou A: Circulating
tumor cells as emerging tumor biomarkers in breast cancer. Clin
Chem Lab Med. 49:1579–1590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fehm T, Müller V, Alix-Panabières C and
Pantel K: Micrometastatic spread in breast cancer: Detection,
molecular characterization and clinical relevance. Breast Cancer
Res. 10(Suppl 1): S12008. View Article : Google Scholar :
|
|
22
|
Lianidou ES and Markou A: Molecular assays
for the detection and characterization of CTCs. Recent Results
Cancer Res. 195:111–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pantel K and Alix-Panabières C: Detection
methods of circulating tumor cells. J Thorac Dis. 4:446–447.
2012.PubMed/NCBI
|
|
24
|
Pantel K and Brakenhoff RH: Dissecting the
metastatic cascade. Nat Rev Cancer. 4:448–456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uhr JW, Huebschman ML, Frenkel EP, Lane
NL, Ashfaq R, Liu H, Rana DR, Cheng L, Lin AT, Hughes GA, et al:
Molecular profiling of individual tumor cells by hyperspectral
microscopic imaging. Transl Res. 159:366–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pantel K, Alix-Panabières C and Riethdorf
S: Cancer micrometastases. Nat Rev Clin Oncol. 6:339–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Geiger TM and Ricciardi R: Screening
options and recommendations for colorectal cancer. Clin Colon
Rectal Surg. 22:209–217. 2009. View Article : Google Scholar :
|
|
28
|
Negin BP and Cohen SJ: Circulating tumor
cells in colorectal cancer: Past, present, and future challenges.
Curr Treat Options Oncol. 11:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim MY, Oskarsson T, Acharyya S, Nguyen
DX, Zhang XH, Norton L and Massagué J: Tumor self-seeding by
circulating cancer cells. Cell. 139:1315–1326. 2009. View Article : Google Scholar
|
|
30
|
Hayes DC, Secrist H, Bangur CS, Wang T,
Zhang X, Harlan D, Goodman GE, Houghton RL, Persing DH and
Zehentner BK: Multigene real-time PCR detection of circulating
tumor cells in peripheral blood of lung cancer patients. Anticancer
Res. 26(2B): 1567–1575. 2006.PubMed/NCBI
|
|
31
|
Saloustros E and Mavroudis D: CTCs in
primary breast cancer (II). Recent Results Cancer Res. 195:187–192.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stathopoulou A, Gizi A, Perraki M,
Apostolaki S, Malamos N, Mavroudis D, Georgoulias V and Lianidou
ES: Real-time quantification of CK-19 mRNA-positive cells in
peripheral blood of breast cancer patients using the lightcycler
system. Clin Cancer Res. 9:5145–5151. 2003.PubMed/NCBI
|
|
33
|
Schoenfeld A, Kruger KH, Gomm J, Sinnett
HD, Gazet JC, Sacks N, Bender HG, Luqmani Y and Coombes RC: The
detection of micrometastases in the peripheral blood and bone
marrow of patients with breast cancer using immunohistochemistry
and reverse transcriptase polymerase chain reaction for keratin 19.
Eur J Cancer. 33:854–861. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ignatiadis M, Xenidis N, Perraki M,
Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou
A, Lianidou E, Chlouverakis G, et al: Different prognostic value of
cyto-keratin-19 mRNA positive circulating tumor cells according to
estrogen receptor and HER2 status in early-stage breast cancer. J
Clin Oncol. 25:5194–5202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xenidis N, Perraki M, Kafousi M,
Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis
N, Kouroussis C, Pallis T, et al: Predictive and prognostic value
of peripheral blood cytokeratin-19 mRNA-positive cells detected by
real-time polymerase chain reaction in node-negative breast cancer
patients. J Clin Oncol. 24:3756–3762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xenidis N, Ignatiadis M, Apostolaki S,
Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G,
Lianidou E, Kakolyris S, et al: Cytokeratin-19 mRNA-positive
circulating tumor cells after adjuvant chemotherapy in patients
with early breast cancer. J Clin Oncol. 27:2177–2184. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xenidis N, Markos V, Apostolaki S, Perraki
M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi
M, Stathopoulos E, et al: Clinical relevance of circulating CK-19
mRNA-positive cells detected during the adjuvant tamoxifen
treatment in patients with early breast cancer. Ann Oncol.
18:1623–1631. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saloustros E, Perraki M, Apostolaki S,
Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A,
Georgoulias V and Mavroudis D: Cytokeratin-19 mRNA-positive
circulating tumor cells during follow-up of patients with operable
breast cancer: Prognostic relevance for late relapse. Breast Cancer
Res. 13:R602011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alix-Panabières C and Pantel K:
Circulating tumor cells: Liquid biopsy of cancer. Clin Chem.
59:110–118. 2013. View Article : Google Scholar
|
|
41
|
Saucedo-Zeni N, Mewes S, Niestroj R,
Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G,
Morgenthaler NG, et al: A novel method for the in vivo isolation of
circulating tumor cells from peripheral blood of cancer patients
using a functionalized and structured medical wire. Int J Oncol.
41:1241–1250. 2012.PubMed/NCBI
|
|
42
|
Sleijfer S, Gratama JW, Sieuwerts AM,
Kraan J, Martens JW and Foekens JA: Circulating tumour cell
detection on its way to routine diagnostic implementation? Eur J
Cancer. 43:2645–2650. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fehm T, Solomayer EF, Meng S, Tucker T,
Lane N, Wang J and Gebauer G: Methods for isolating circulating
epithelial cells and criteria for their classification as carcinoma
cells. Cytotherapy. 7:171–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Königsberg R, Obermayr E, Bises G, Pfeiler
G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M and
Dittrich C: Detection of EpCAM positive and negative circulating
tumor cells in meta-static breast cancer patients. Acta Oncol.
50:700–710. 2011. View Article : Google Scholar
|
|
45
|
Sieuwerts AM, Kraan J, Bolt-de Vries J,
van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S and
Foekens JA: Molecular characterization of circulating tumor cells
in large quantities of contaminating leukocytes by a multiplex
real-time PCR. Breast Cancer Res Treat. 118:455–468. 2009.
View Article : Google Scholar
|
|
46
|
Schindlbeck C, Stellwagen J, Jeschke U,
Karsten U, Rack B, Janni W, Jückstock J, Tulusan A, Sommer H and
Friese K: Immunomagnetic enrichment of disseminated tumor cells in
bone marrow and blood of breast cancer patients by the
Thomsen-Friedenreich-Antigen. Clin Exp Metastasis. 25:233–240.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vona G, Sabile A, Louha M, Sitruk V,
Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, et
al: Isolation by size of epithelial tumor cells : A new method for
the immunomorphological and molecular characterization of
circulatingtumor cells. Am J Pathol. 156:57–63. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Busch R, Cesar D, Higuera-Alhino D, Gee T,
Hellerstein MK and McCune JM: Isolation of peripheral blood
CD4+ T cells using RosetteSep and MACS for studies of
DNA turnover by deuterium labeling. J Immunol Methods. 286:97–109.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hayes DF and Smerage JB: Circulating tumor
cells. Prog Mol Biol Transl Sci. 95:95–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Riethdorf S, Fritsche H, Müller V, Rau T,
Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, et al:
Detection of circulating tumor cells in peripheral blood of
patients with metastatic breast cancer: A validation study of the
CellSearch system. Clin Cancer Res. 13:920–928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cristofanilli M: The biological
information obtainable from circulating tumor cells. Breast.
18(Suppl 3): S38–S40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW, et al: Circulating tumor cells, disease progression,
and survival in metastatic breast cancer. N Engl J Med.
351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nolé F, Munzone E, Zorzino L, Minchella I,
Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N,
et al: Variation of circulating tumor cell levels during treatment
of metastatic breast cancer: Prognostic and therapeutic
implications. Ann Oncol. 19:891–897. 2008. View Article : Google Scholar
|
|
54
|
Bidard FC, Mathiot C, Delaloge S, Brain E,
Giachetti S, de Cremoux P, Marty M and Pierga JY: Single
circulating tumor cell detection and overall survival in
nonmetastatic breast cancer. Ann Oncol. 21:729–733. 2010.
View Article : Google Scholar
|
|
55
|
Botteri E, Sandri MT, Bagnardi V, Munzone
E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A,
Curigliano G, et al: Modeling the relationship between circulating
tumour cells number and prognosis of metastatic breast cancer.
Breast Cancer Res Treat. 122:211–217. 2010. View Article : Google Scholar
|
|
56
|
Jakob C, Aust DE, Liebscher B, Baretton
GB, Datta K and Muders MH: Lymphangiogenesis in regional lymph
nodes is an independent prognostic marker in rectal cancer patients
after neoadjuvant treatment. PLoS One. 6:e274022011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Miller MC, Doyle GV and Terstappen LW:
Significance of circulating tumor cells detected by the CellSearch
system in patients with metastatic breast colorectal and prostate
cancer. J Oncol. 2010:6174212010. View Article : Google Scholar
|
|
58
|
Farace F, Massard C, Vimond N, Drusch F,
Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L,
Planchard D, et al: A direct comparison of CellSearch and ISET for
circulating tumour-cell detection in patients with metastatic
carcinomas. Br J Cancer. 105:847–853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Alix-Panabières C: EPISPOT assay:
Detection of viable DTCs/CTCs in solid tumor patients. Recent
Results Cancer Res. 195:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Alix-Panabières C, Vendrell JP, Pellé O,
Rebillard X, Riethdorf S, Müller V, Fabbro M and Pantel K:
Detection and characterization of putative metastatic precursor
cells in cancer patients. Clin Chem. 53:537–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Somlo G, Lau SK, Frankel P, Hsieh HB, Liu
X, Yang L, Krivacic R and Bruce RH: Multiple biomarker expression
on circulating tumor cells in comparison to tumor tissues from
primary and metastatic sites in patients with locally
advanced/inflammatory, and stage IV breast cancer, using a novel
detection technology. Breast Cancer Res Treat. 128:155–163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Alix-Panabières C, Vendrell JP, Slijper M,
Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M and Pantel K:
Full-length cyto-keratin-19 is released by human tumor cells: A
potential role in metastatic progression of breast cancer. Breast
Cancer Res. 11:R392009. View Article : Google Scholar
|
|
64
|
Fehm T, Sagalowsky A, Clifford E, Beitsch
P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, et
al: Cytogenetic evidence that circulating epithelial cells in
patients with carcinoma are malignant. Clin Cancer Res.
8:2073–2084. 2002.PubMed/NCBI
|
|
65
|
Swennenhuis JF, Tibbe AG, Levink R,
Sipkema RC and Terstappen LW: Characterization of circulating tumor
cells by fluorescence in situ hybridization. Cytometry A.
75:520–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Issadore D, Chung J, Shao H, Liong M,
Ghazani AA, Castro CM, Weissleder R and Lee H: Ultrasensitive
clinical enumeration of rare cells ex vivo using a micro-hall
detector. Sci Transl Med. 4:141ra922012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Stott SL, Hsu CH, Tsukrov DI, Yu M,
Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK,
et al: Isolation of circulating tumor cells using a
microvortex-generating herringbone-chip. Proc Natl Acad Sci USA.
107:18392–18397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sun YY, Lu M, Xi XW, Qiao QQ, Chen LL, Xu
XM and Feng YJ: Regulation of epithelial-mesenchymal transition by
homeobox gene DLX4 in JEG-3 trophoblast cells: A role in
preeclampsia. Reprod Sci. 18:1138–1145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang X, Qian X, Beitler JJ, Chen ZG, Khuri
FR, Lewis MM, Shin HJ, Nie S and Shin DM: Detection of circulating
tumor cells in human peripheral blood using surface-enhanced Raman
scattering nanoparticles. Cancer Res. 71:1526–1532. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Deng G, Herrler M, Burgess D, Manna E,
Krag D and Burke JF: Enrichment with anti-cytokeratin alone or
combined with anti-EpCAM antibodies significantly increases the
sensitivity for circulating tumor cell detection in metastatic
breast cancer patients. Breast Cancer Res. 10:R692008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wang L, Wang Y, Liu Y, Cheng M, Wu X and
Wei H: Flow cytometric analysis of CK19 expression in the
peripheral blood of breast carcinoma patients: Relevance for
circulating tumor cell detection. J Exp Clin Cancer Res. 28:572009.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bustin SA and Mueller R: Real-time reverse
transcription PCR (qRT-PCR) and its potential use in clinical
diagnosis. Clin Sci (Lond). 109:365–379. 2005. View Article : Google Scholar
|
|
75
|
Dubois V, Delort L, Mishellany F, Jarde T,
Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP and
Caldefie-Chezet F: Zinc-alpha2-glycoprotein: A new biomarker of
breast cancer? Anticancer Res. 30:2919–2925. 2010.PubMed/NCBI
|
|
76
|
Fabisiewicz A, Kulik J, Kober P,
Brewczyńska E, Pieńkowski T and Siedlecki JA: Detection of
circulating breast cancer cells in peripheral blood by a two-marker
reverse transcriptase-polymerase chain reaction assay. Acta Biochim
Pol. 51:747–755. 2004.PubMed/NCBI
|
|
77
|
Ring A, Smith IE and Dowsett M:
Circulating tumour cells in breast cancer. Lancet Oncol. 5:79–88.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Van der Auwera I, Peeters D, Benoy IH,
Elst HJ, Van Laere SJ, Prové A, Maes H, Huget P, van Dam P,
Vermeulen PB, et al: Circulating tumour cell detection: A direct
comparison between the CellSearch System, the AdnaTest and
CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.
Br J Cancer. 102:276–284. 2010. View Article : Google Scholar :
|
|
79
|
Gibson UE, Heid CA and Williams PM: A
novel method for real time quantitative RT-PCR. Genome Res.
6:995–1001. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bustin SA: Absolute quantification of mRNA
using real-time reverse transcription polymerase chain reaction
assays. J Mol Endocrinol. 25:169–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ginzinger DG: Gene quantification using
real-time quantitative PCR: An emerging technology hits the
mainstream. Exp Hematol. 30:503–512. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wittwer CT, Herrmann MG, Moss AA and
Rasmussen RP: Continuous fluorescence monitoring of rapid cycle DNA
amplification. Biotechniques. 22:130–131. 134–138. 1997.PubMed/NCBI
|
|
83
|
Ke LD, Chen Z and Yung WK: A reliability
test of standard-based quantitative PCR: Exogenous vs endogenous
standards. Mol Cell Probes. 14:127–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:Research00342002. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pfaffl MW, Lange IG, Daxenberger A and
Meyer HH: Tissue-specific expression pattern of estrogen receptors
(ER): Quantification of ER alpha and ER beta mRNA with real-time
RT-PCR. APMIS. 109:345–355. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hocquette JF and Brandstetter AM: Common
practice in molecular biology may introduce statistical bias and
misleading biological interpretation. J Nutr Biochem. 13:370–377.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ririe KM, Rasmussen RP and Wittwer CT:
Product differentiation by analysis of DNA melting curves during
the polymerase chain reaction. Anal Biochem. 245:154–160. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Elnifro EM, Ashshi AM, Cooper RJ and
Klapper PE: Multiplex PCR: Optimization and application in
diagnostic virology. Clin Microbiol Rev. 13:559–570. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Max N, Wolf K, Thiel E and Keilholz U:
Quantitative nested real-time RT-PCR specific for tyrosinase
transcripts to quantitate minimal residual disease. Clin Chim Acta.
317:39–46. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Halford WP: The essential prerequisites
for quantitative RT-PCR. Nat Biotechnol. 17:8351999. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Orlando C, Pinzani P and Pazzagli M:
Developments in quantitative PCR. Clin Chem Lab Med. 36:255–269.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ghossein RA, Carusone L and Bhattacharya
S: Molecular detection of micrometastases and circulating tumor
cells in melanoma prostatic and breast carcinomas. In Vivo.
14:237–250. 2000.PubMed/NCBI
|
|
93
|
Cone RW, Hobson AC and Huang ML:
Coamplified positive control detects inhibition of polymerase chain
reactions. J Clin Microbiol. 30:3185–3189. 1992.PubMed/NCBI
|
|
94
|
Gerges N, Rak J and Jabado N: New
technologies for the detection of circulating tumour cells. Br Med
Bull. 94:49–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Chen TF, Jiang GL, Fu XL, Wang LJ, Qian H,
Wu KL and Zhao S: CK19 mRNA expression measured by
reverse-transcription polymerase chain reaction (RT-PCR) in the
peripheral blood of patients with non-small cell lung cancer
treated by chemoradiation: An independent prognostic factor. Lung
Cancer. 56:105–114. 2007. View Article : Google Scholar
|
|
96
|
Lambrechts AC, Bosma AJ, Klaver SG, Top B,
Perebolte L, van' t Veer LJ and Rodenhuis S: Comparison of
immunocytochemistry, reverse transcriptase polymerase chain
reaction, and nucleic acid sequence-based amplification for the
detection of circulating breast cancer cells. Breast Cancer Res
Treat. 56:219–231. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lianidou ES and Markou A: Circulating
tumor cells in breast cancer: Detection systems, molecular
characterization, and future challenges. Clin Chem. 57:1242–1255.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Pantel K, Brakenhoff RH and Brandt B:
Detection, clinical relevance and specific biological properties of
disseminating tumour cells. Nat Rev Cancer. 8:329–340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gabert J, Beillard E, van der Velden VH,
Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela
JM, Cavé H, et al: Standardization and quality control studies of
'real-time' quantitative reverse transcriptase polymerase chain
reaction of fusion gene transcripts for residual disease detection
in leukemia - a Europe Against Cancer program. Leukemia.
17:2318–2357. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Müller V, Witzel I, Lück HJ, Köhler G, von
Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, et
al: Prognostic and predictive impact of the HER-2/neu extracellular
domain (ECD) in the serum of patients treated with chemotherapy for
metastatic breast cancer. Breast Cancer Res Treat. 86:9–18. 2004.
View Article : Google Scholar
|
|
101
|
Niesters HG: Standardization and quality
control in molecular diagnostics. Expert Rev Mol Diagn. 1:129–131.
2001. View Article : Google Scholar
|
|
102
|
Niesters HG and Puchhammer-Stöckl E:
Standardisation and controls, why can't we overcome the hurdles? J
Clin Virol. 31:81–83. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Raengsakulrach B, Nisalak A, Maneekarn N,
Yenchitsomanus PT, Limsomwong C, Jairungsri A, Thirawuth V, Green
S, Kalayanarooj S, Suntayakorn S, et al: Comparison of four reverse
transcription-polymerase chain reaction procedures for the
detection of dengue virus in clinical specimens. J Virol Methods.
105:219–232. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Mostert B, Sleijfer S, Foekens JA and
Gratama JW: Circulating tumor cells (CTCs): Detection methods and
their clinical relevance in breast cancer. Cancer Treat Rev.
35:463–474. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Paterlini-Brechot P and Benali NL:
Circulating tumor cells (CTC) detection: Clinical impact and future
directions. Cancer Lett. 253:180–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ignatiadis M, Kallergi G, Ntoulia M,
Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E,
Lianidou E, Georgoulias V, et al: Prognostic value of the molecular
detection of circulating tumor cells using a multimarker reverse
transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2
in early breast cancer. Clin Cancer Res. 14:2593–2600. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kowalewska M, Chechlińska M, Markowicz S,
Kober P and Nowak R: The relevance of RT-PCR detection of
disseminated tumour cells is hampered by the expression of markers
regarded as tumour-specific in activated lymphocytes. Eur J Cancer.
42:2671–2674. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Suchy B, Austrup F, Driesel G, Eder C,
Kusiak I, Uciechowski P, Grill HJ and Giesing M: Detection of
mammaglobin expressing cells in blood of breast cancer patients.
Cancer Lett. 158:171–178. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Jiang Y, Harlocker SL, Molesh DA, Dillon
DC, Stolk JA, Houghton RL, Repasky EA, Badaro R, Reed SG and Xu J:
Discovery of differentially expressed genes in human breast cancer
using subtracted cDNA libraries and cDNA microarrays. Oncogene.
21:2270–2282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ignatiadis M, Perraki M, Apostolaki S,
Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E,
Sotiriou C, Georgoulias V, et al: Molecular detection and
prognostic value of circulating cytokeratin-19 messenger
RNA-positive and HER2 messenger RNA-positive cells in the
peripheral blood of women with early-stage breast cancer. Clin
Breast Cancer. 7:883–889. 2007. View Article : Google Scholar
|
|
112
|
Slade MJ, Smith BM, Sinnett HD, Cross NC
and Coombes RC: Quantitative polymerase chain reaction for the
detection of micrometastases in patients with breast cancer. J Clin
Oncol. 17:870–879. 1999.PubMed/NCBI
|
|
113
|
Stathopoulou A, Mavroudis D, Perraki M,
Apostolaki S, Vlachonikolis I, Lianidou E and Georgoulias V:
Molecular detection of cancer cells in the peripheral blood of
patients with breast cancer: Comparison of CK-19, CEA and maspin as
detection markers. Anticancer Res. 23(2C): 1883–1890.
2003.PubMed/NCBI
|
|
114
|
Stathopoulou A, Ntoulia M, Perraki M,
Apostolaki S, Mavroudis D, Malamos N, Georgoulias V and Lianidou
ES: A highly specific real-time RT-PCR method for the quantitative
determination of CK-19 mRNA positive cells in peripheral blood of
patients with operable breast cancer. Int J Cancer. 119:1654–1659.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Silva HA, Abraúl E, Raimundo D, Dias MF,
Marques C, Guerra C, de Oliveira CF and Regateiro FJ: Molecular
detection of EGFRvIII-positive cells in the peripheral blood of
breast cancer patients. Eur J Cancer. 42:2617–2622. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Gargano G, Agnese V, Calò V, Corsale S,
Augello C, Bruno L, La Paglia L, Gullo A, Ottini L, Russo A, et al
Gruppo Oncologico dell'Italia Meridionale: Detection and
quantification of mammaglobin in the blood of breast cancer
patients: Can it be useful as a potential clinical marker?
Preliminary results of a GOIM (Gruppo Oncologico dell'Italia
Meridionale) prospective study. Ann Oncol. 17(Suppl 7):
vii41–vii45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mercatali L, Valenti V, Calistri D,
Calpona S, Rosti G, Folli S, Gaudio M, Frassineti GL, Amadori D and
Flamini E: RT-PCR determination of maspin and mammaglobin B in
peripheral blood of healthy donors and breast cancer patients. Ann
Oncol. 17:424–428. 2006. View Article : Google Scholar
|
|
118
|
Ntoulia M, Stathopoulou A, Ignatiadis M,
Malamos N, Mavroudis D, Georgoulias V and Lianidou ES: Detection of
Mammaglobin A-mRNA-positive circulating tumor cells in peripheral
blood of patients with operable breast cancer with nested RT-PCR.
Clin Biochem. 39:879–887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Fantl V, Smith R, Brookes S, Dickson C and
Peters G: Chromosome 11q13 abnormalities in human breast cancer.
Cancer Surv. 18:77–94. 1993.PubMed/NCBI
|
|
120
|
Fleming TP and Watson MA: Mammaglobin, a
breast-specific gene, and its utility as a marker for breast
cancer. Ann NY Acad Sci. 923:78–89. 2000. View Article : Google Scholar
|
|
121
|
Ceballos MP, Zumoffen C, Massa E, Cipulli
G, Funes CC, Gil AB, Morales C, Tozzini R and Ghersevich S:
Detection of mammaglogin A in blood from breast cancer patients,
before and after treatment, using a one-tube nested PCR protocol.
Association with the absence of tumor estrogen receptors. Clin
Biochem. 44:1429–1433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Corradini P, Voena C, Astolfi M, Delloro
S, Pilotti S, Arrigoni G, Bregni M, Pileri A and Gianni AM: Maspin
and mammaglobin genes are specific markers for RT-PCR detection of
minimal residual disease in patients with breast cancer. Ann Oncol.
12:1693–1698. 2001. View Article : Google Scholar
|
|
123
|
Ferro P, Franceschini MC, Bacigalupo B,
Dessanti P, Falco E, Fontana V, Gianquinto D, Pistillo MP, Fedeli F
and Roncella S: Detection of circulating tumour cells in breast
cancer patients using human mammaglobin RT-PCR: Association with
clinical prognostic factors. Anticancer Res. 30:2377–2382.
2010.PubMed/NCBI
|
|
124
|
Roncella S, Ferro P, Bacigalupo B,
Pronzato P, Tognoni A, Falco E, Gianquinto D, Ansaldo V, Dessanti
P, Fais F, et al: Human mammaglobin mRNA is a reliable molecular
marker for detecting occult breast cancer cells in peripheral
blood. J Exp Clin Cancer Res. 24:265–271. 2005.PubMed/NCBI
|
|
125
|
Silva AL, Tomé MJ, Correia AE and
Passos-Coelho JL: Human mammaglobin RT-PCR assay for detection of
occult breast cancer cells in hematopoietic products. Ann Oncol.
13:422–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ballestrero A, Garuti A, Bertolotto M,
Rocco I, Boy D, Nencioni A, Ottonello L and Patrone F: Effect of
different cytokines on mammaglobin and maspin gene expression in
normal leukocytes: Possible relevance to the assays for the
detection of micrometastatic breast cancer. Br J Cancer.
92:1948–1952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Cerveira N, Torres L, Rocha P, Bizarro S,
Pereira D, Abreu J, Henrique R, Teixeira MR and Castedo S: Highly
sensitive detection of the MGB1 transcript (mammaglobin) in the
peripheral blood of breast cancer patients. Int J Cancer.
108:592–595. 2004. View Article : Google Scholar
|
|
128
|
Zach O, Kasparu H, Krieger O, Hehenwarter
W, Girschikofsky M and Lutz D: Detection of circulating mammary
carcinoma cells in the peripheral blood of breast cancer patients
via a nested reverse transcriptase polymerase chain reaction assay
for mammaglobin mRNA. J Clin Oncol. 17:2015–2019. 1999.PubMed/NCBI
|
|
129
|
Silva JM, Domínguez G, González-Sancho JM,
García JM, Silva J, García-Andrade C, Navarro A, Muñoz A and
Bonilla F: Expression of thyroid hormone receptor/erbA genes is
altered in human breast cancer. Oncogene. 21:4307–4316. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Tewes M, Aktas B, Welt A, Mueller S, Hauch
S, Kimmig R and Kasimir-Bauer S: Molecular profiling and predictive
value of circulating tumor cells in patients with metastatic breast
cancer: An option for monitoring response to breast cancer related
therapies. Breast Cancer Res Treat. 115:581–590. 2009. View Article : Google Scholar
|
|
131
|
Shen C, Hu L, Xia L and Li Y: The
detection of circulating tumor cells of breast cancer patients by
using multimarker (Survivin, hTERT and hMAM) quantitative real-time
PCR. Clin Biochem. 42:194–200. 2009. View Article : Google Scholar
|
|
132
|
Zehentner BK, Persing DH, Deme A, Toure P,
Hawes SE, Brooks L, Feng Q, Hayes DC, Critichlow CW, Houghton RL,
et al: Mammaglobin as a novel breast cancer biomarker: Multigene
reverse transcription-PCR assay and sandwich ELISA. Clin Chem.
50:2069–2076. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Monteiro J and Fodde R: Cancer stemness
and metastasis: Therapeutic consequences and perspectives. Eur J
Cancer. 46:1198–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Sabbah M, Emami S, Redeuilh G, Julien S,
Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O and Gespach C:
Molecular signature and therapeutic perspective of the
epithelial-to-mesenchymal transitions in epithelial cancers. Drug
Resist Updat. 11:123–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Thompson R: Cancer: Epithelial subtype
influences the prognosis of invasive IPMN. Nat Rev Gastroenterol
Hepatol. 8:4202011. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gradilone A, Raimondi C, Nicolazzo C,
Petracca A, Gandini O, Vincenzi B, Naso G, Aglianò AM, Cortesi E
and Gazzaniga P: Circulating tumour cells lacking cytokeratin in
breast cancer: The importance of being mesenchymal. J Cell Mol Med.
15:1066–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bednarz-Knoll N, Alix-Panabières C and
Pantel K: Plasticity of disseminating cancer cells in patients with
epithelial malignancies. Cancer Metastasis Rev. 31:673–687. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Smirnov DA, Zweitzig DR, Foulk BW, Miller
MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno
JG, et al: Global gene expression profiling of circulating tumor
cells. Cancer Res. 65:4993–4997. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
de Albuquerque A, Kaul S, Breier G,
Krabisch P and Fersis N: Multimarker analysis of circulating tumor
cells in peripheral blood of metastatic breast cancer patients: A
step forward in personalized medicine. Breast Care (Basel). 7:7–12.
2012. View Article : Google Scholar
|
|
141
|
Lowes LE and Allan AL: Recent advances in
the molecular characterization of circulating tumor cells. Cancers
(Basel). 6:595–624. 2014. View Article : Google Scholar
|
|
142
|
Grover PK, Cummins AG, Price TJ,
Roberts-Thomson IC and Hardingham JE: Circulating tumour cells: The
evolving concept and the inadequacy of their enrichment by
EpCAM-based methodology for basic and clinical cancer research. Ann
Oncol. 25:1506–1516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Liu X and Fan D: The
epithelial-mesenchymal transition and cancer stem cells: Functional
and mechanistic links. Curr Pharm Des. 21:1279–1291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Čabiňaková M and Tesařová P: Disseminated
and circulating tumour cells and their role in breast cancer. Folia
Biol (Praha). 58:87–97. 2012.
|
|
145
|
Daskalaki A, Agelaki S, Perraki M,
Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D,
Mavroudis D and Georgoulias V: Detection of cytokeratin-19
mRNA-positive cells in the peripheral blood and bone marrow of
patients with operable breast cancer. Br J Cancer. 101:589–597.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Andergassen U, Hofmann S, Kölbl AC,
Schindlbeck C, Neugebauer J, Hutter S, Engelstädter V, Ilmer M,
Friese K and Jeschke U: Detection of tumor cell-specific mRNA in
the peripheral blood of patients with breast cancer-evaluation of
several markers with real-time reverse transcription-PCR. Int J Mol
Sci. 14:1093–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Cierna Z, Mego M, Janega P, Karaba M,
Minarik G, Benca J, Sedlácková T, Cingelova S, Gronesova P,
Manasova D, et al: Matrix metalloproteinase 1 and circulating tumor
cells in early breast cancer. BMC Cancer. 14:4722014. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Cheng M, Chen Y, Zou D, Shen G, Bian G,
Shen G and Hu S: The clinical utility of circulating tumor cells in
breast cancer patients: Detection by a quantitative assay of h-MAM
gene expression. Int J Biol Markers. 29:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Xi L, Nicastri DG, El-Hefnawy T, Hughes
SJ, Luketich JD and Godfrey TE: Optimal markers for real-time
quantitative reverse transcription PCR detection of circulating
tumor cells from melanoma, breast, colon, esophageal, head and
neck, and lung cancers. Clin Chem. 53:1206–1215. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Lasa A, Garcia A, Alonso C, Millet P,
Cornet M, Ramón Y, Cajal T, Baiget M and Barnadas A: Molecular
detection of peripheral blood breast cancer mRNA transcripts as a
surrogate biomarker for circulating tumor cells. PLoS One.
8:e740792013. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Skondra M, Gkioka E, Kostakis ID,
Pissimissis N, Lembessis P, Pectasides D and Koutsilieris M:
Detection of circulating tumor cells in breast cancer patients
using multiplex reverse transcription-polymerase chain reaction and
specific primers for MGB, PTHRP and KRT19 correlation with
clinicopathological features. Anticancer Res. 34:6691–6699.
2014.PubMed/NCBI
|
|
152
|
Zebisch M, Kölbl AC, Schindlbeck C,
Neugebauer J, Heublein S, Ilmer M, Rack B, Friese K, Jeschke U and
Andergassen U: Quantification of breast cancer cells in peripheral
blood samples by real-time RT-PCR. Anticancer Res. 32:5387–5391.
2012.PubMed/NCBI
|
|
153
|
Guo M, Li X, Zhang S, Song H, Zhang W,
Shang X, Zheng Y, Jiang H, Lv Q, Jiang Y, et al: Real-time
quantitative RT-PCR detection of circulating tumor cells from
breast cancer patients. Int J Oncol. 46:281–289. 2015.
|
|
154
|
Pinzani P, Salvadori B, Simi L, Bianchi S,
Distante V, Cataliotti L, Pazzagli M and Orlando C: Isolation by
size of epithelial tumor cells in peripheral blood of patients with
breast cancer: Correlation with real-time reverse
transcriptase-polymerase chain reaction results and feasibility of
molecular analysis by laser microdissection. Hum Pathol.
37:711–718. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Nakagawa T, Martinez SR, Goto Y, Koyanagi
K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE,
et al: Detection of circulating tumor cells in early-stage breast
cancer metastasis to axillary lymph nodes. Clin Cancer Res.
13:4105–4110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin
W, Kumar D, Goodman JC, Groves MD and Marchetti D: The
identification and characterization of breast cancer CTCs competent
for brain metastasis. Sci Transl Med. 5:180ra482013. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Androulakis N, Agelaki S, Perraki M,
Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A,
Mavroudis D and Georgoulias V: Clinical relevance of circulating
CK-19mRNA-positive tumour cells before front-line treatment in
patients with metastatic breast cancer. Br J Cancer. 106:1917–1925.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Georgoulias V, Apostolaki S, Bozionelou V,
Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A,
Xyrafas A, Agelaki S, et al: Effect of front-line chemotherapy on
circulating CK-19 mRNA-positive cells in patients with metastatic
breast cancer. Cancer Chemother Pharmacol. 74:1217–1225. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Xenidis N, Perraki M, Apostolaki S,
Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris
S, Mavroudis D, et al: Differential effect of adjuvant taxane-based
and taxane-free chemotherapy regimens on the CK-19 mRNA-positive
circulating tumour cells in patients with early breast cancer. Br J
Cancer. 108:549–556. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wang HY, Ahn S, Kim S, Park S, Park S, Han
H, Sohn JH, Kim S and Lee H: Detection of circulating tumor cells
in patients with breast cancer using the quantitative RT-PCR assay
for monitoring of therapy efficacy. Exp Mol Pathol. 97:445–452.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Ušiaková Z, Mikulová V, Pintérová D,
Brychta M, Valchář J, Kubecová M, Tesařová P, Bobek V and Kološtová
K: Circulating tumor cells in patients with breast cancer:
Monitoring chemotherapy success. In Vivo. 28:605–614.
2014.PubMed/NCBI
|
|
162
|
Mikulová V, Cabiňaková M, Janatková I,
Mestek O, Zima T and Tesařová P: Detection of circulating tumor
cells during follow-up of patients with early breast cancer:
Clinical utility for monitoring of therapy efficacy. Scand J Clin
Lab Invest. 74:132–142. 2014. View Article : Google Scholar
|
|
163
|
Mego M, Mani SA, Lee BN, Li C, Evans KW,
Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, et al:
Expression of epithelial-mesenchymal transition-inducing
transcription factors in primary breast cancer: The effect of
neoadjuvant therapy. Int J Cancer. 130:808–816. 2012. View Article : Google Scholar
|
|
164
|
Baccelli I, Stenzinger A, Vogel V,
Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M,
Holland-Letz T, Sinn HP, et al: Co-expression of MET and CD47 is a
novel prognosticator for survival of luminal breast cancer
patients. Oncotarget. 5:8147–8160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Sterzynska K, Kempisty B, Zawierucha P and
Zabel M: Analysis of the specificity and selectivity of anti-EpCAM
antibodies in breast cancer cell lines. Folia Histochem Cytobiol.
50:534–541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Markiewicz A, Książkiewicz M, Seroczyńska
B, Skokowski J, Szade J, Wełnicka-Jaśkiewicz M and Zaczek AJ:
Heterogeneity of mesenchymal markers expression-molecular profiles
of cancer cells disseminated by lymphatic and hematogenous routes
in breast cancer. Cancers (Basel). 5:1485–1503. 2013. View Article : Google Scholar
|
|
167
|
Serrano MJ, Ortega FG, Alvarez-Cubero MJ,
Nadal R, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL,
Delgado-Rodriguez M, Solé F, et al: EMT and EGFR in CTCs
cytokeratin negative non-metastatic breast cancer. Oncotarget.
5:7486–7497. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Sieuwerts AM, Mostert B, Bolt-de Vries J,
Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van
Galen A, de Weerd V, et al: mRNA and microRNA expression profiles
in circulating tumor cells and primary tumors of metastatic breast
cancer patients. Clin Cancer Res. 17:3600–3618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Shaw JA, Brown J, Coombes RC, Jacob J,
Payne R, Lee B, Page K, Hava N and Stebbing J: Circulating tumor
cells and plasma DNA analysis in patients with indeterminate early
or metastatic breast cancer. Biomarkers Med. 5:87–91. 2011.
View Article : Google Scholar
|
|
170
|
Peeters DJ, Brouwer A, Van den Eynden GG,
Rutten A, Onstenk W, Sieuwerts AM, Van Laere SJ, Huget P, Pauwels
P, Peeters M, et al: Circulating tumour cells and lung
microvascular tumour cell retention in patients with metastatic
breast and cervical cancer. Cancer Lett. 356(2 Pt B): 872–879.
2015. View Article : Google Scholar
|
|
171
|
Kurata H, Takakuwa K, Tsuneki I, Aoki Y
and Tanaka K: Ovarian tumor cell detection in peripheral blood
progenitor cells harvests by RT-PCR. Acta Obstet Gynecol Scand.
81:555–559. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Oikonomopoulou K, Scorilas A, Michael IP,
Grass L, Soosaipillai A, Rosen B, Murphy J and Diamandis EP:
Kallikreins as markers of disseminated tumour cells in ovarian
cancer: a pilot study. Tumour Biol. 27:104–114. 2006. View Article : Google Scholar
|
|
173
|
Magnowski P, Bochyński H, Nowak-Markwitz
E, Zabel M and Spaczyński M: Circulating tumor cells
(CTCs)–clinical significance in patients with ovarian cancer.
Ginekol Pol. 83:291–294. 2012.In Polish. PubMed/NCBI
|
|
174
|
Poveda A, Kaye SB, McCormack R, Wang S,
Parekh T, Ricci D, Lebedinsky CA, Tercero JC, Zintl P and Monk BJ:
Circulating tumor cells predict progression free survival and
overall survival in patients with relapsed/recurrent advanced
ovarian cancer. Gynecol Oncol. 122:567–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Romero-Laorden N, Olmos D, Fehm T,
Garcia-Donas J and Diaz-Padilla I: Circulating and disseminated
tumor cells in ovarian cancer: A systematic review. Gynecol Oncol.
133:632–639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Liu JF, Kindelberger D, Doyle C, Lowe A,
Barry WT and Matulonis UA: Predictive value of circulating tumor
cells (CTCs) in newly-diagnosed and recurrent ovarian cancer
patients. Gynecol Oncol. 131:352–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Aktas B, Kasimir-Bauer S, Heubner M,
Kimmig R and Wimberger P: Molecular profiling and prognostic
relevance of circulating tumor cells in the blood of ovarian cancer
patients at primary diagnosis and after platinum-based
chemotherapy. Int J Gynecol Cancer. 21:822–830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Obermayr E, Castillo-Tong DC, Pils D,
Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I and
Zeillinger R: Molecular characterization of circulating tumor cells
in patients with ovarian cancer improves their prognostic
significance - a study of the OVCAD consortium. Gynecol Oncol.
128:15–21. 2013. View Article : Google Scholar
|
|
179
|
Pearl ML, Zhao Q, Yang J, Dong H, Tulley
S, Zhang Q, Golightly M, Zucker S and Chen WT: Prognostic analysis
of invasive circulating tumor cells (iCTCs) in epithelial ovarian
cancer. Gynecol Oncol. 134:581–590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Zeng L, Liang X, Liu Q and Yang Z: The
predictive value of circulating tumor cells in ovarian cancer: A
meta analysis. Int J Gynecol Cancer. Apr 17–2015.Epub ahead of
print.
|
|
181
|
Song J and Nettles JB: Circulating tumor
cells in patients with carcinoma in situ of the cervix uteri. Am J
Obstet Gynecol. 104:713–726. 1969.PubMed/NCBI
|
|
182
|
Yuan CC, Wang PH, Ng HT, Li YF, Huang TS,
Chen CY, Tsai LC and Shyong WY: Detecting cytokeratin 19 mRNA in
the peripheral blood cells of cervical cancer patients and its
clinical-pathological correlation. Gynecol Oncol. 85:148–153. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Weismann P, Weismanova E, Masak L, Mlada
K, Keder D, Ferancikova Z, Vizvaryova M, Konecny M, Zavodna K,
Kausitz J, et al: The detection of circulating tumor cells
expressing E6/E7 HR-HPV oncogenes in peripheral blood in cervical
cancer patients after radical hysterectomy. Neoplasma. 56:230–238.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Alonso-Alconada L, Muinelo-Romay L,
Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D,
Coenegrachts L, Cano A, et al ENITEC Consortium: Molecular
profiling of circulating tumor cells links plasticity to the
metastatic process in endometrial cancer. Mol Cancer. 13:2232014.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Bogani G, Liu MC, Dowdy SC, Cliby WA, Kerr
SE, Kalli KR, Kipp BR, Halling KC, Campion MB and Mariani A:
Detection of circulating tumor cells in high-risk endometrial
cancer. Anticancer Res. 35:683–687. 2015.PubMed/NCBI
|
|
186
|
Grünewald K, Haun M, Fiegl M, Urbanek M,
Müller-Holzner E, Massoner A, Riha K, Propst A, Marth C and Gastl
G: Mammaglobin expression in gynecologic malignancies and malignant
effusions detected by nested reverse transcriptase-polymerase chain
reaction. Lab Invest. 82:1147–1153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Obermayr E, Sanchez-Cabo F, Tea MK, Singer
CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R,
Heinze G, et al: Assessment of a six gene panel for the molecular
detection of circulating tumor cells in the blood of female cancer
patients. BMC Cancer. 10:6662010. View Article : Google Scholar : PubMed/NCBI
|
